MCRB

1.2406.77%
ED

Eric D. Shaff

Director

Mr. Eric D. Shaff, M.B.A., is President and Director of Psivant Therapeutics, Inc and is Chief Executive Officer from December 2025. Mr. Shaff served as President and Chief Executive Officer at Seres Therapeutics, Inc. since January 15, 2019 until July 31, 2025 and serves as its Director since January 2019. He served as Chief Operating Officer at Seres Therapeutics, Inc. since January 2018 until January 2019 and served as its Chief Financial Officer and Treasurer since November 2014 until January 2019. Mr. Shaff was Executive Vice President of Seres Therapeutics, Inc. from January 2018 until January 2019 and served as Principal Accounting Officer. He served as its Interim Principal Financial Officer until 2019. He served as Secretary of Seres Therapeutics, Inc. From January 2012 to November 2014, Mr. Shaff served as Vice President of Corporate Finance at Momenta Pharmaceuticals, Inc., where he helped manage Momenta's financial management including planning, financial control, procurement and Investor Relations. Mr. Shaff has been the President and Chief Executive Officer of PsiThera, Inc. since September 2025. Mr. Shaff has many years of corporate biotech finance and development experience. Prior to Momenta, he served as Global Head of Finance at Genzyme Corporation's Rare Genetic Disease Division and held several positions at Genzyme in Business Unit Finance and Corporate Finance as well as Corporate Development since June 2004 till December 2011. From June 2004 to December 2011, Mr. Shaff held a number of corporate development and finance positions with Genzyme Corporation, most recently as Vice President of Finance/Controller for the Personalized Genetic Health division. Previously, he worked in Corporate Finance at Pfizer and worked in investment banking for Broadview International (now Jefferies Broadview). He is an experienced business leader with exceptional strategic and operational acumen and the Board has great confidence in his ability to successfully lead Seres. He has extensive experience in the biotechnology field. Mr. Shaff had been Independent Director of Sigilon Therapeutics, Inc. since November 2017 until August 11, 2023. Mr. Shaff earned his BA from the University of Pennsylvania in Political Science and Economics. He earned his MBA from the Johnson Graduate School of Management at Cornell University with a concentration in Finance.

Positions